Breaking AI & Tech News Analyzed

The world is facing an energy crisis reminiscent of the 1970s, with rising energy prices and fears of stagflation. In response, countries may turn to coal, a dirtiest of fuels, to meet their energy demands.Historically, energy crises have led to increased investment in coal production. During Jimmy Carter's presidency, the US aggressively developed domestic coal sources, which became America's 'black hope'. Similarly, Donald Trump's America is doubling down on fossil fuels, pushing to develop US coal and oil reserves.The energy crisis sparked by the US-Iran war highlights the need for renewable energy sources. However, the conflict has raised hurdles to investing in renewable power generation capacity, including inflation and interest rates. As a result, countries around the world, including Japan, India, and Europe, are considering or have already ramped up their use of coal.Despite the progress made in decarbonization and the switch to cleaner gas in power generation, the current crisis could unravel these efforts. Coal consumption worldwide has increased by about 1.3bn tons since 2020, to 8.8bn tons, driven by demand in India and China. The International Energy Agency (IEA) reports that coal supplied 23% of the world's energy in 2000, increasing to 28% in 2023.The global energy landscape is shifting, with renewable energy sources becoming increasingly important. However, the ongoing conflict in Iran and rising energy prices pose significant challenges to the transition to a low-carbon economy.

When screenwriter Daisy Goodwin examined Prince Albert’s habit of selecting Victoria’s bonnets, she wondered whether the gesture signified tender devotion or a more unsettling dominance. The question becomes the backbone of her new stage drama, which recasts the iconic Victorian marriage as a case of coercive control rather than a model partnership. Set in the waning days of Victoria’s reign at Windsor, the production opens with Amanda Boxer portraying an aging monarch—a weary, self‑pitying figure cloaked in black bombazine. Her character, a compulsive diarist, fears that her candid journals might be released after her death, a concern that fuels the play’s tension. Designer Alex Berry creates a slanted, reflective ceiling that acts like a distorted mirror of memory, underscoring Victoria’s claim that her diaries are “the only place where I could be completely honest”. Yet the presence of Albert, played by Rowan Polonski, suggests that even these private pages were never truly safe. Jessica Rhodes brings youthful Victoria to life, initially buoyant as she waltzes with Albert. The romance quickly darkens as Albert’s behavior shifts to manipulating her ambitions and curbing her joy. He pressures her into motherhood—she dismisses the children as “invincibly tedious”—and intrudes on her official duties, from speeches to industrial tours. In a biting line, she accuses him of making “the monarchy so boring that no one was awake enough to start a revolution”. The play’s narrative moves from teasing banter to overt control, with intimate moments on the sofa devolving into fierce arguments over gifts (“You gave me a brooch made of teeth, Albert!”). A poignant scene where Victoria reads from Jane Eyre hints at a gothic destiny that Goodwin imagines Albert may have plotted. While Goodwin’s empathy clearly leans toward Victoria, the production also raises contemporary expectations of royalty, suggesting that public service—not romantic idealisation—should define modern monarchs. Director Sophie Drake’s brisk pacing navigates the play’s contradictions, ultimately unsettling the long‑held myth of a contented, untroubled royal household. The production runs at the Watermill Theatre in Newbury until 9 May, offering audiences a fresh, critical lens on a celebrated historical partnership.

The World Health Organisation (WHO) has issued a stern warning against the ongoing US-Israeli attacks on Iranian healthcare facilities, amid the escalating conflict. The organisation's chief, Tedros Adhanom Ghebreyesus, reported that over 20 attacks on healthcare facilities in Iran have been verified since March 1, resulting in at least nine deaths, including an infectious diseases health worker and a member of the Iranian Red Crescent Society.The Pasteur Institute in Tehran, one of the oldest research and health facilities in the country, has sustained significant damage and was rendered unable to continue delivering health services. Iranian Ministry of Health spokesperson Hossein Kermanpour shared images of the heavily damaged building on social media, with parts of the facility reduced to rubble.Despite the attacks, Iran's ISNA news agency reported that the services of the Pasteur Institute have not been interrupted, and vaccine and serum production would continue. The WHO chief emphasised that the Institute plays a crucial role in protecting and promoting population health, particularly in emergencies.The attacks have not been limited to the Pasteur Institute. The WHO has reported damage to other healthcare facilities, including the Delaram Sina Psychiatric Hospital and the Tofigh Daru pharmaceutical facility, with no casualties reported. An explosion near the Imam Ali Hospital in Khuzestan province led to the facility's evacuation and cessation of services.Tedros stressed that humanitarian workers, ambulances, relief supplies, and humanitarian facilities must be respected and protected under international law. The Geneva Conventions, agreed upon after World War II, designate healthcare facilities as protected locations.The Iranian Red Crescent Society reported that a warehouse belonging to the organisation was targeted, destroying two-wheeled relief containers and two buses and relief vehicles. According to the organisation, 307 health, medical, and emergency care facilities have been damaged in the war.

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.

American consumers are watching gasoline and airline fares climb, while economists warn that the war in Iran will keep pressure on prices across the U.S. economy.“The good old days are gone,” said Christopher Tang, a professor at UCLA’s Anderson School of Management who studies global supply chains. “We see gasoline prices rising now, but that’s only the tip of the iceberg; everything will become more expensive.”Since the conflict began in late February, crude oil has surged past $110 a barrel. The rally is tied to Iran’s leverage over the Strait of Hormuz, a narrow chokepoint through which roughly 20% of the world’s oil passes.In a recent address, President Donald Trump claimed the United States is “totally independent of the Middle East” and has “plenty of gas.” However, Brookings Institute’s energy‑security director Samantha Gross reminded listeners that oil is a globally traded commodity and the U.S. still imports significant volumes, meaning American consumers will face the same high prices as the rest of the world.Iran has either halted shipments through the strait or imposed a toll of up to $2 million per vessel. Tankers are forced to take longer routes or pay the fee, inflating logistics costs for all downstream users.Major logistics players are already passing those costs on. Amazon announced a 3.5% surcharge for third‑party sellers, while UPS and FedEx have introduced fuel surcharges exceeding 25%. The United States Postal Service will add an 8% surcharge to transportation rates starting 27 April, noting the charge is “less than one‑third of what our competitors charge for fuel alone.”When the prices go up, they rarely come back down— Christopher Tang, UCLACountries have dipped into strategic oil reserves to blunt the shock, but economists such as Virginia Tech’s David Bieri warn that refilling those stockpiles will require buying oil at today’s elevated prices, keeping the upward pressure on the market.Higher oil costs ripple beyond fuel. Crude is a key feedstock for chemicals, pharmaceuticals and fertilizers, meaning the surge could translate into higher prices for prescription drugs and groceries.Cornell University’s agricultural economics professor Christopher Wolf explained that diesel, a major input for farm equipment and fertilizer production, is also climbing, raising the cost of both crop cultivation and livestock raising.Retailers and food processors are already adjusting. “If we anticipate higher costs, we start raising prices early to avoid a sudden shock later,” Wolf said, describing a “rational expectations” approach.The Independent Grocers Alliance warned that a 10‑15% rise in fuel costs could lift food prices by 2‑4% by mid‑summer, underscoring the broader impact on household budgets.Although President Trump expects the United States to exit the Iran conflict within two to three weeks, experts agree that even a swift resolution will not instantly reverse the price spikes.The strait’s strategic importance means the political risk premium on oil will linger. “You never know when this could flare up again,” said Northeastern University’s Ravi Ramamurti, adding that the effect is likely to be persistent.As Tang summed up, “When the prices go up, they rarely come back down.”

Mary Beth Hurt died on 28 March 2026 at the age of 79, closing a four‑decade career that blended intellectual cinema with acclaimed stage work. Born in Marshalltown, Iowa, she entered the film world with Woody Allen’s experimental drama Interiors (1978), earning a BAFTA nomination for Best Newcomer alongside Christopher Reeve.Although Interiors was a modest critical success, it proved financially profitable, grossing $10 million on a $3 million budget. Hurt’s portrayal of the directionless Joey marked the start of a career defined by thoughtful, understated performances.Her next high‑profile role came as Helen Holm, the college‑professor wife of Robin Williams’s titular character in The World According to Garp (1982). The film’s daring tonal shifts – including a shocking car‑crash scene – earned Oscar nominations for John Lithgow and Glenn Close, while giving Hurt a rare chance to play a fully sexual woman.Early setbacks included losing the lead in Joan Micklin Silver’s Head Over Heels (1979) to Jamie Lee Curtis and a troubled turn in the melodrama A Change of Seasons (1980), which suffered from production turmoil and poor box‑office returns.On stage, Hurt distinguished herself with three Tony nominations: for Pinero’s Trelawny of the ‘Wells’ (1976) opposite a debuting Meryl Streep, for a 1982 revival of Beth Henley’s Crimes of the Heart, and for Michael Frayn’s Benefactors (1986). She debuted on Broadway in 1974’s revival of William Congreve’s Love For Love opposite Glenn Close.Her personal life intersected with her professional world. She married fellow actor William Hurt in 1971, divorcing in December 1982, and later wed director Paul Schrader in August 1983. Collaborations with Schrader included Light Sleeper (1992), Affliction (1997) and The Walker (2007).Later film work featured a supporting turn in Karen Moncrieff’s feminist thriller The Dead Girl (2006), which earned her an Independent Spirit Award nomination, and a cameo in Martin Scorsese’s The Age of Innocence (1993). Her final screen appearance was in the small‑town drama Change in the Air (2018), filmed before a diagnosis of Alzheimer’s disease.Reflecting on her craft, Hurt once said, "I never felt very beautiful or incredibly smart or witty, so I was always looking for something about the role that intrigued me… more fascinating than the gold‑medal moments."She is survived by husband Paul Schrader and their two children, Molly and Sam.

AI‑Driven Power Race The AI boom is prompting the biggest wave of power‑infrastructure investment since the early days of cloud computing. Companies are scrambling to lock in natural‑gas supplies and build on‑site generators, a move that could reshape electricity markets in the southern United States. Scale of the Projects Microsoft is partnering with Chevron and Engine No. 1 to construct a natural‑gas plant in West Texas that could reach 5 GW of capacity. Google has confirmed a collaboration with Crusoe for a 933 MW plant in North Texas. Meta is adding seven more plants to its Hyperion data‑center complex in Louisiana, bringing total on‑site capacity to 7.46 GW—enough, the company notes, to power the entire state of South Dakota. Combined, these projects exceed 13 GW, roughly equivalent to the average electricity demand of a mid‑size U.S. state. Supply Constraints and Cost Pressures Wood Mackenzie warns that turbine prices have surged 195% versus 2019 levels. If a 2020 turbine cost $1 million, the same unit now costs about $2.95 million, inflating the equipment share of a plant’s budget from 20% to up to 30%. The consultancy also notes a six‑year lead time for turbine delivery, meaning new orders cannot be placed until 2028. This bottleneck could delay the rollout of additional capacity precisely when AI workloads are accelerating. Resource Availability and Market Risks The U.S. Geological Survey estimates that a single gas‑rich region holds enough supply to power the entire United States for 10 months. While abundant, production growth in the three leading shale basins—responsible for three‑quarters of U.S. output—has slowed, tightening the long‑term outlook. Natural gas accounts for about 40% of U.S. electricity generation (EIA). Consequently, any spike in gas prices reverberates through wholesale electricity markets, raising the cost of power for all consumers, not just data‑center operators. Strategic Risks for Tech Companies Behind‑the‑meter gas plants allow firms to claim “self‑supply,” but they merely shift demand from the public grid to the gas grid, potentially driving up wholesale gas prices. Industrial users—petrochemical plants, fertilizer manufacturers—cannot easily substitute gas with renewables, so they may push back against large‑scale data‑center consumption. Extreme weather, such as the 2021 Texas freeze, can curtail wellhead output, forcing a choice between keeping AI workloads online or supplying heat to households. In sum, the AI‑driven rush for natural‑gas power plants highlights a fundamental physical constraint: the digital economy still depends on finite, market‑sensitive energy resources. Betting heavily on a commodity that can swing dramatically in price may prove costly if AI growth plateaus or if gas supply tightens.

The conflict between the US and Israel against Iran has taken a devastating toll on the country's healthcare system. At least 2,076 people have been killed and 26,500 wounded in Iran since the US and Israel first launched strikes on the country on February 28.Iranian President Masoud Pezeshkian has strongly condemned the attacks, appealing to international health organizations to respond to the crisis. On Thursday, he wrote on X: “What message does attacking hospitals, pharmaceutical companies and the Pasteur Institute as a medical research center in Iran convey?”The Pasteur Institute, a key center for medical research and vaccine production in Tehran, has been targeted. The institute, founded over 100 years ago in collaboration with the Institut Pasteur in Paris, conducts research on infectious diseases, produces vaccines, and provides advanced diagnostics.According to the World Health Organization (WHO), over 20 attacks on healthcare facilities in Iran have been verified since March 1, resulting in at least nine deaths, including an infectious diseases health worker and a member of the Iranian Red Crescent Society.Some of the facilities hit include:Red Crescent warehouse in Bushehr province, which was destroyed by a drone strike on Friday morning.Tofigh Daru Research and Engineering Company, one of Iran’s largest pharmaceutical companies, which was hit on March 31.Delaram Sina Psychiatric Hospital in Tehran, which was significantly damaged on March 29.Ali Hospital in Andimeshk, which sustained damage from an explosion on March 21.Gandhi Hospital in Tehran, which was damaged during attacks on a nearby television communications tower on March 2.International humanitarian law states that health establishments and units, including hospitals, should not be attacked. The United Nations Security Council resolution 2286 was adopted unanimously in 2016, condemning attacks on healthcare and calling on nations to respect international law.The attacks on healthcare facilities are not limited to Iran. Israel has also targeted healthcare facilities in Lebanon and Gaza, resulting in significant damage and loss of life.

Ukraine has made significant gains on the battlefield, halving the Russian rate of advance in the past three months and reclaiming 470sq km of occupied territory this year. The country's military has also dealt a major blow to Russia's oil export capacity, striking key terminals and refineries, including Ust-Luga and Primorsk, which account for about 60% of Russia's oil export capacity.Ukrainian President Volodymyr Zelenskyy has secured agreements with several Gulf states, including Saudi Arabia, the UAE, and Qatar, to export Ukrainian drone know-how in return for joint drone production support. This has enabled Ukraine to increase its drone production and effectively counter Russian advances.The Ukrainian military has also targeted Russian munitions production, striking the Promsintez explosives plant in the Samara region, which produces 30,000 tonnes of military explosives annually. According to estimates, Russia has lost 45% of its missile production capacity due to Ukrainian strikes.In response to Ukrainian attacks, Russia has begun to extend its drone strikes throughout the day, imitating Iran's tactics against the US and Israel. However, Ukraine has successfully shot down over 90% of the drones launched by Russia.